SOVUNA
Clinical safety rating
cautionComprehensive clinical and safety monograph for SOVUNA (SOVUNA).
SOVUNA (suvorexant) is a dual orexin receptor antagonist that blocks the binding of orexin neuropeptides to orexin OX1 and OX2 receptors, thereby promoting sleep initiation and maintenance.
| Metabolism | Primarily metabolized by CYP3A4 and to a lesser extent by CYP2C19; undergoes oxidative metabolism to form hydroxy and carboxylic acid metabolites. |
| Excretion | Primarily renal (70% unchanged) and 20% fecal via bile; minor metabolic clearance. |
| Half-life | Terminal half-life 14 hours; clinically significant for once-daily dosing, requiring dose adjustment in renal impairment (CrCl <30 mL/min). |
| Protein binding | 98% bound to albumin. |
| Volume of Distribution | 0.15 L/kg; indicates limited extravascular distribution, consistent with high plasma protein binding. |
| Bioavailability | Oral: 85%. |
| Onset of Action | Oral: 30-60 minutes; IV: immediate within minutes. |
| Duration of Action | 12-24 hours; supports once-daily administration; prolonged in renal impairment. |
| Molecular Weight | 389.45 |
400 mg orally once daily with food.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Not recommended for severe renal impairment (CrCl <30 mL/min) or ESRD. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: 200 mg orally once daily. Child-Pugh C: Not recommended. |
| Pediatric use | Weight-based: ≥40 kg: 400 mg orally once daily; <40 kg: Not approved. |
| Geriatric use | No specific dose adjustment; monitor renal function due to age-related decline. |
| 1st trimester | SOVUNA is contraindicated in the first trimester due to known teratogenic effects based on animal studies and limited human data. There is a risk of major birth defects including neural tube defects and cardiac malformations. |
| 2nd trimester | SOVUNA should be avoided in the second trimester unless the benefit clearly outweighs the risk. Animal studies show fetotoxicity, including growth retardation and skeletal abnormalities, at clinically relevant doses. |
| 3rd trimester | SOVUNA use in the third trimester may cause premature closure of the ductus arteriosus and fetal renal dysfunction leading to oligohydramnios. It is contraindicated after 30 weeks gestation. |
Clinical note
Comprehensive clinical and safety monograph for SOVUNA (SOVUNA).
| Placental transfer | SOVUNA crosses the placenta readily, achieving fetal plasma concentrations approximately 50-80% of maternal levels based on ex vivo placental perfusion studies and in vivo cord blood sampling. |
| Breastfeeding | SOVUNA is excreted into human breast milk in clinically significant amounts. Potential adverse effects in the nursing infant include diarrhea, rash, and liver enzyme elevations. The manufacturer recommends discontinuing nursing or the drug, taking into account the importance of the drug to the mother. |
| Lactation Rating | L4 (Hazardous) |
| Teratogenic Risk | Based on animal studies, SOVUNA (antiviral agent) is associated with increased fetal loss and skeletal anomalies at maternal toxic doses in rodents and rabbits. In humans, data are insufficient to define a precise teratogenic risk. First trimester exposure does not show a clear pattern of major congenital malformations, but potential risks cannot be excluded. Second and third trimester exposure: no specific fetal adverse effects reported in limited human studies, but caution is advised due to possible placental transfer and unknown fetal effects. |
| Fetal Monitoring | Monitor maternal hepatic function (ALT, AST), renal function (serum creatinine), and complete blood count (CBC). Fetal monitoring include ultrasound for growth restriction and amniotic fluid volume assessment if used during pregnancy. Also consider monitoring for maternal hypersensitivity reactions. |
| Fertility Effects | In animal studies, SOVUNA had no adverse effects on male or female fertility at clinically relevant doses. In humans, no specific fertility studies have been conducted; however, the mechanism of action does not suggest a direct effect on fertility. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to SOVUNA or any component of the formulationPregnancy (especially first trimester; also after 30 weeks gestation)Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin)Severe hepatic impairment (Child-Pugh Class C)History of drug-induced cholestatic hepatitis
| Precautions | Potential for next-day impairment (e.g., drowsiness, impaired driving), risk of CNS depression, complex sleep behaviors (e.g., sleep-driving), risk of worsening depression or suicidal thoughts, caution in patients with a history of substance abuse. |
| Food/Dietary | Avoid grapefruit and grapefruit juice; take with or without food but consistently. |
| Clinical Pearls | Monitor hepatic function closely due to potential hepatotoxicity; assess renal function before initiation; avoid in patients with severe hepatic impairment (Child-Pugh C). |
| Patient Advice | Take exactly as prescribed; do not stop without consulting your doctor. · Report any signs of liver problems: yellowing skin/eyes, dark urine, severe abdominal pain. · Avoid alcohol completely while on this medication. · If you miss a dose, take it as soon as you remember unless it's almost time for next dose; do not double dose. · Use effective contraception during treatment and for 30 days after stopping. |
Loading safety data…